December 2018 Volume 14, Issue 12
Volume 14, Issue 12 | December 2018
December 2018
In this Issue
Business & Government Policy
The long and short reads of it
Illumina aims at a more comprehensive sequencing offering with the acquisition of PacBioPartners in immuno-oncology
MorphoSys and I-Mab sign strategic agreement for novel immuno-oncology agent MOR210An acquisition and a contract in infectious disease
Sobi to acquire Synagis rights from AstraZeneca for RSV; Tulane awarded NIH contract for whooping coughOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsDiscovery
The two faces of AMPK
Salk scientists unravel how enzyme long thought to suppress cancer may sometimes help tumors surviveHeal thyself—with a little boost
Sitryx and Sygnature join hands to develop therapeutics in immuno-oncology and immuno-inflammationTargeting tumors with TRPV6
Drug candidate minimizes cancer cell growth with minimal side effectsGoing after Parkinson’s disease with iPS cells
Keio University and Eisai open path to new techniques for developing neurological therapeuticsNovel approaches to obesity and metabolic disease
Novo Seeds incubatee Embark Biotech enters collaboration with Novo NordiskPreclinical
Innovate looking for answers about NASH
Company studies the effects of larazotide on nonalcoholic fatty liver diseaseNegating nicotine
Scripps scientists test enzyme to reduce dependenceHeralding HERA-CD27L
Preclinical efficacy data of Apogenix compound published in Frontiers in OncologyPreventing heart disease in cancer survivors
CDK2 protein said to play critical role in heart damage caused by doxorubicin, a common chemotherapy drugFeature
Focus Feature on Cancer Research: Combating cancer with creativity
A collection of some of the newest approaches to targeting cancer cellsCommentary
Publishers’ commentary: A year in review and a year’s preview
The publishers of DDNews check in with their annual look back and look forward for readers of the magazine and visitors of our websitesTransparency vs. opacity
The will to understand vs. the will to obscure is not a new theme, but when blended with electronic communications it is given new intensityGuest Commentary: A more reproducible approach to creating functional Th17 cells
A look at the importance of Th17 cells for drug discovery and look at how the use of specialized methods to confirm cellular identity provides a level of validation that has not previously been availableContract Services
CROs lead industry-wide shift to modernize trial processes
Roughly nine of 10 CROs are taking steps to unify clinical operations for better visibility and improved study executionAdvancing biomarker discovery and therapeutic development
Specialized CRO offers high-definition tissue imaging services for pharmaceutical and clinical researchDiamond Pharma named best specialist CRO
Business award granted at OBN in recognition of expert services in cell and gene therapyClinical Trials
New combo therapy for pancreatic cancer?
Pairing investigational peptide with Keytruda yields promising results for BioLineRxAttacking alopecia areata
Concert reveals results for drug to counter autoimmune attack against hair folliclesLOXL2 inhibitor combats fibrosis
Pharmaxis releases positive results of Phase 1 clinical trial for second LOXL2 inhibitor compoundPositive data for brain cancer treatment
Ziopharm provides update on Controlled IL-12 platform at Society for Neuro-Oncology meetingAgainst atrial fibrillation
GENETIC-AF Phase 2B AFB results presented at AHA 2018 meetingResearch & Development
Fast, open and free analysis with BioJupies
Mount Sinai researchers develop tool that analyzes biomedical data within minutesUnderstanding Zika’s methods
New lab technique helps reveal how Zika virus manipulates the immune system by stripping immune cells of their identityA challenge for Alzheimer’s innovation
Business leader fuels global, multimillion-dollar Oskar Fischer ProjectDiagnostics
Myriad makes strides in companion diagnostics
Company announces results for ovarian cancer and an approval for breast cancerDigging in deep for diagnostics
Companies continue efforts to develop tests for early Alzheimer’s diagnosisTesting the waters in genetic screening
Nonprofits co-fund feasibility study to test screening tool for 75,000 newborns for Angelman, Prader-Willi, fragile X and Dup15q syndromesThyGenX and ThyraMIR data show positive results
Interpace Diagnostics presents favorable new study findings at the 88th Annual Meeting of the American Thyroid Association
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
A closer look at the tumor microenvironment
New technologies are allowing researchers to delve deeper into the complex tumor landscape.
Exploring stain-free western blotting
Researchers can achieve seamless western blot experiments by implementing advancements in stain-free technology, normalization methods, and compliance integration.
Streamlining biopharmaceutical analysis with digital solutions
Discover how digitization improves data integrity and accelerates decision-making in biotherapeutics development.
